Atossa Therapeutics receives Nasdaq extension to Feb 17, 2026 for bid price compliance

ATOSSA THERAPEUTICS, INC.

Nasdaq notified Atossa on Feb 21, 2025 of non-compliance with $1.00 min bid price rule.
Initial compliance period ended Aug 20, 2025; extension granted to Feb 17, 2026.
Company may consider a reverse stock split to regain compliance.
No immediate impact on Nasdaq listing or trading of ATOS shares.
Atossa is monitoring bid price and evaluating available options.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.